SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15 (d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): December 13, 2005

                             SIGA TECHNOLOGIES, INC.
             (Exact name of registrant as specified in its charter)

           Delaware                     0-23047                  13-3864870
(State or other jurisdiction of       (Commission             (I.R.S. employer
incorporation or organization)        file number)           identification no.)

420 Lexington Avenue, Suite 408
      New York, New York
    (Address of principal                                          10170
      executive offices)                                         (Zip code)

       Registrant's telephone number, including area code: (212) 672-9100

      -------------------------------------------------------------------------

      Check the appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))



Item 8.01 Other Events.

      On December  13, 2005,  SIGA  Technologies,  Inc., a Delaware  corporation
("SIGA"),  issued a press release pursuant to which SIGA announced that the U.S.
Food and Drug  Administration  (FDA) accepted its Investigational New Drug (IND)
application  to begin Phase I clinical  trials of  SIGA-246,  its lead  smallpox
drug. SIGA also announced that in order to expedite the program, the FDA granted
SIGA-246 Fast-Track status.

      A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(c)   Exhibits

Exhibit No.     Description
-----------     -----------

99.1            Press Release, dated December 13, 2005.


                                      -2-


                                    SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                        SIGA TECHNOLOGIES, INC.


                                        By: /s/ Thomas N. Konatich
                                            -------------------------------
                                            Name:   Thomas N. Konatich
                                            Title:  Chief Financial Officer

Date:  December 14, 2005


                                      -3-